Pfizer announces partnership to develop stem cell-based therapies for ophthalmic conditions
Posted on 27 April 2009
Pfizer’s Regenerative Medicine unit announced that it signed an agreement with University College London aimed at developing stem cell-based therapies primarily for wet and dry macular degeneration, as well as other retinal diseases. As part of the collaboration, Pfizer gains exclusive worldwide rights to develop and market a retinal pigment epithelium (RPE) stem cell-based treatment.
Under the terms of the agreement, Pfizer will provide funding to the university to enable research into the development of such therapies, as well as offer its expertise in clinical trials, interaction with global regulators and product manufacturing techniques. In addition, following the completion of pre-clinical testing, the drugmaker will have the option to conduct further trials and market any potential product resulting from the collaboration.
Ruth McKernan, chief scientific officer of Pfizer Regenerative Medicine, did not disclose financial details of the partnership but said the drugmaker plans to invest $100 million in stem-cell research in the coming three to five years.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment